menu
    • menu
    [{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ethris \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ DIOSynVax"},{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"NI007","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ethris \/ Neurimmune","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Neurimmune"},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Series B Financing","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ethris \/ Laureus Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ Laureus Capital"},{"orgOrder":0,"company":"Ethris","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"ETH51","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Ethris \/ Heqet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Heqet Therapeutics"},{"orgOrder":0,"company":"Ethris","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ETH45","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ethris \/ Cipla","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Cipla"},{"orgOrder":0,"company":"Ethris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ETH47","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ethris \/ Inapplicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"ETH52","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Ethris \/ Ethris","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Ethris"},{"orgOrder":0,"company":"Ethris","sponsor":"EU4Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2025","type":"Funding","leadProduct":"ETH47","moa":"IFN-lambda","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Ethris","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Nasal Inhalation","sponsorNew":"Ethris \/ EU4Health","highestDevelopmentStatusID":"8","companyTruncated":"Ethris \/ EU4Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Ethris

    Menu

    Ethris

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : EU4Health

                            Deal Size : $11.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Ethris Gets €10M EU4Health Grant to Advance ETH47 mRNA Antiviral Program

                            Details : The funding will support NoVir, a comprehensive project including several preclinical and clinical studies to evaluate the potential of ETH47, Ethris’ lead, first-in-class mRNA-based therapy.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : EU4Health

                            Deal Size : $11.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH52

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ethris And Lonza Team Up For Spray-Dried mRNA Respiratory Vaccines

                            Details : The initial focus of the collaboration is to develop a first-in-class mRNA vaccine candidate against influenza delivered nasally.

                            Product Name : ETH52

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 07, 2025

                            Lead Product(s) : ETH52

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : Lonza Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ETH47 Phase 1 Data Shows Promise for Uncontrolled Asthma Treatment

                            Details : ETH47 is a lead mRNA candidate encoding interferon lambda (IFNλ). It is being evaluated in the early-stage clinical trial studies for the treatment of asthma.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ethris Announces Positive Initial Phase 1 Data for ETH47 mRNA Nasal Delivery

                            Details : ETH47 is a lead mRNA candidate encoding interferon lambda (IFNλ). It is being evaluated in the early-stage clinical trial studies for the treatment of asthma.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            June 25, 2024

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study

                            Details : The funding aims to support the company first-in-class mRNA-based product candidate ETH47, which is being evaluated in the early-stage clinical trial studies for the treatment of asthma.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            June 18, 2024

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-induced Asthma

                            Details : ETH47 is a first-in-class, broadly protective antiviral candidate which is under phase 1 clinical development for the treatment and prophylaxis of viral asthma exacerbations.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 18, 2023

                            Lead Product(s) : ETH47

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH47

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory V...

                            Details : MHRA approved company to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47 (induce a mucosal innate immune defense), in healthy participants for the treatment and prophylaxis of respiratory viral infections.

                            Product Name : ETH47

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 28, 2023

                            Lead Product(s) : ETH47

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH51

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Heqet Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and He...

                            Details : Under the terms of the agreement, Heqet will lead the development of ETH51, RNA-based therapeutics for heart attack and heart failure, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the ...

                            Product Name : ETH51

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 13, 2023

                            Lead Product(s) : ETH51

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Heqet Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETH45

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : Cipla

                            Deal Size : $16.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cipla EU to Invest EUR 15 Million In Ethris, Initiating A Strategic Collaboration

                            Details : ETH45 is a first-in-class inhalable form of Ethris’ proprietary mRNA for treatment of pulmonary alveolar proteinosis (PAP). ETH45 activates granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in the presence of anti-GM-CF antibodies.

                            Product Name : ETH45

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 29, 2022

                            Lead Product(s) : ETH45

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : Cipla

                            Deal Size : $16.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Ethris

                            Germany arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : $42.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Be...

                            Details : Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 dis...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 21, 2022

                            Lead Product(s) : mRNA-Based COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : DIOSynVax

                            Deal Size : $42.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth